{"keywords":["BRAF","NRAS","localized","melanoma","prognosis","survival"],"meshTags":["Proto-Oncogene Proteins B-raf","Melanoma","Mutation","Prognosis","Kaplan-Meier Estimate","Neoplasm Invasiveness","Retrospective Studies","Skin Neoplasms","Proportional Hazards Models","Humans","Disease-Free Survival"],"meshMinor":["Proto-Oncogene Proteins B-raf","Melanoma","Mutation","Prognosis","Kaplan-Meier Estimate","Neoplasm Invasiveness","Retrospective Studies","Skin Neoplasms","Proportional Hazards Models","Humans","Disease-Free Survival"],"genes":["BRAF mutations","BRAF","BRAF mutations","BRAF","BRAF-wt genotype","BRAF mutation"],"publicationTypes":["Journal Article","Observational Study","Research Support, Non-U.S. Gov\u0027t"],"abstract":"BRAF mutations are frequent in melanoma but their prognostic significance remains unclear.\nWe sought to further evaluate the prognostic value of BRAF mutations in localized cutaneous melanoma.\nWe undertook an observational retrospective study of 147 patients with localized invasive (stages I and II) cutaneous melanomas to determine the prognostic value of BRAF mutation status.\nAfter a median follow-up of 48 months, patients with localized melanomas with BRAF-mutant melanomas exhibited poorer disease-free survival than those with BRAF-wt genotype (hazard ratio 2.2, 95% confidence interval 1.1-4.3) even after adjustment for Breslow thickness, tumor ulceration, location, age, sex, and tumor mitotic rate.\nThe retrospective design and the small number of events are limitations.\nOur findings suggest that reappraisal of clinical treatment approaches for patients with localized melanoma harboring tumors with BRAF mutation might be warranted.","title":"Prognostic value of BRAF mutations in localized cutaneous melanoma.","pubmedId":"24388723"}